Skip to main content

Table 4 Clinical features of 144 NAFLD patients and 257 healthy controls with very low probability of steatosis from Northern Italy according to the PNPLA3 I148M genotype

From: The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls

 

NAFLD patients (n = 144)

p value*

PNPLA3 genotype

CC (n = 55)

CG (n = 68)

GG (n = 21)

 

Age (years)

49±13

51±12

47±12

0.87

Sex (F)

15 (27)

12 (18)

5 (24)

0.58

BMI (Kg/m2)

26.8±3.7

27.1±3.1

26.0±3.0

0.62

ALT (IU/ml)

54±38

58±49

80±54

0.06

Diabetes

3 (5.5)

11 (16.2)

3 (14.3)

0.13

Insulin (IU/ml)

14.6 {11.7-19.9}

13.4 {10.2-20.2}

16.8 {11.5-22.1}

0.33

Glucose

94±21

101±34

97±16

0.43

HOMA-IR

3.1 {2.5-4.5}

3.3 {2.4-4.5}

3.3 {2.4-5.5}

0.57

FFAs (mmol/l)

0.21±0.09

0.22±0.08

0.22±0.09

0.85

Adipo-IR

14.2±15.1

13.9±13.9

17.9±15.4

0.78

Adiponectin (μg/ml)

5.5 {3.0-9.9}

4.9 {3.0-7.4}

3.8 {2.7-6.5}

0.03

 

Controls (n = 257)

p value*

PNPLA3 genotype

CC (n = 146)

CG (n = 95)

GG (n = 16)

 

Age (years)

46±12

51±12

45±14

0.51

Sex (F)

37 (25)

15 (16)

3 (19)

0.83

BMI (Kg/m2)

24.8±2.7

25.2±2.8

25.2±4.2

0.71

ALT (IU/ml)

21±7

24±8

22±6

0.48

Insulin° (IU/ml)

11.8 {9.5-14.0}

11.9 {9.2-15.4}

9.0 {7.6-14.8}

0.17

Glucose

89±6

89±6

86±3

0.89

HOMA-IR°

2.5 {1.9-3.2}

2.6 {2.0-3.4}

1.8 {1.7-3.0}

0.10

FFAs° (mmol/l)

0.16±0.07

0.14±0.06

0.23±0.02

0.93

Adipo-IR°

6.4±2.8

5.2±2.1

8.1±0.9

0.47

Adiponectin (μg/ml)

7.0 {4.7-9.9}

6.2 {4.7-8.8}

5.6 {4.2-7.4}

0.04

  1. * p for trend across PNPLA3 genotypes, °available in 68 controls. BMI body mass index, IFG impaired fasting glucose, HOMA-IR homeostasis model assessment insulin resistance index, FFAs free fatty acids, Adipo-IR adipose tissue insulin resistance index, ():% values, {}: interquartile range.